Dupont Capital Management’s Kyntra Bio KYNB Stock Holding History

Dupont Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-201	Closed	-$206K	–	1338
2020 Q3	$206K	Buy	+201	New	+$216K	﹤0.01%	1108
2020 Q2	–	Sell	-312	Closed	-$271K	–	1378
2020 Q1	$271K	Hold	312	–	–	0.01%	906
2019 Q4	$335K	Sell	312 -349	-53%	-$356K	0.01%	1034
2019 Q3	$611K	Sell	661 -57	-8%	-$62.6K	0.01%	703
2019 Q2	$811K	Buy	718 +84	+13%	+$91.9K	0.02%	605
2019 Q1	$862K	Hold	634	–	–	0.02%	590
2018 Q4	$734K	Buy	634 +330	+109%	+$371K	0.02%	618
2018 Q3	$462K	Buy	+304	New	+$468K	0.01%	733
2018 Q1	–	Sell	-700	Closed	-$829K	–	968
2017 Q4	$829K	Sell	700 -238	-25%	-$298K	0.02%	557
2017 Q3	$1.26M	Hold	938	–	–	0.03%	480
2017 Q2	$757K	Buy	+938	New	+$653K	0.02%	589

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Dupont Capital Management's KYNB Position: Q4 2020 in Review

Dupont Capital Management sold out of Kyntra Bio (KYNB) in Q4 2020, closing a stake of 201 shares — an estimated $206K sold.

Dupont Capital Management first reported a position in KYNB in Q2 2017 and held it in 11 quarters. The position peaked at $1.26M in Q3 2017. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

Dupont Capital Management reported no remaining Kyntra Bio position as of Q4 2020 after selling out during the quarter.
Dupont Capital Management sold 201 Kyntra Bio shares in Q4 2020, an estimated $206K.
Dupont Capital Management first reported a position in Kyntra Bio in Q2 2017 and held it in 11 quarters.
Dupont Capital Management's Kyntra Bio position peaked at $1.26M in Q3 2017.
207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on Dupont Capital Management's 13F filing for Q4 2020, filed 28 Jan 2021.